Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.44 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684519 | 0.93 | MAPT (0.45) | MCHR1MCHR2POLBMAPK1HTR3A | |
| SCHEMBL4688854 | 0.92 | CCR3 (0.45) | MCHR1POLBMAPK1CCR3MAPT | |
| SCHEMBL4683061 | 0.91 | MCHR1 (0.45) | MCHR1MCHR2POLBMAPK1HTR3A | |
| SCHEMBL4236281 | 0.89 | TAS1R3 (0.45) | MCHR1MCHR2HTR4ALDH1A1MAPT | |
| SCHEMBL4688007 | 0.89 | CCR3 (0.44) | MCHR1POLBCCR3MAPT | |
| SCHEMBL4690097 | 0.89 | CCR3 (0.45) | MCHR1MCHR2POLBDRD2DRD3 | |
| SCHEMBL4684563 | 0.88 | KDR (0.44) | MCHR1DRD2DRD3CCR3 | |
| SCHEMBL4689230 | 0.88 | CCR3 (0.42) | MCHR1POLBMAPK1DRD2DRD3 | |
| SCHEMBL4683789 | 0.86 | MEN1 (0.44) | MCHR1MCHR2POLBDRD2DRD3 | |
| SCHEMBL4688728 | 0.85 | MCHR1 (0.47) | MCHR1MCHR2HTR3AHTR4QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885MCHR2 30/4885POLB 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.